8
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found

      Endocrinological Environment of Polycystic Ovarian Disease

      review-article
      ,
      Hormone Research in Paediatrics
      S. Karger AG
      Gonadotropins, PRL, PCOD, Dopamine, Metoclopramide

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Serum levels of androgenic hormones, 17-hydroxyprogesterone and estrone in Japanese patients with polycystic ovarian disease (PCOD) were elevated as compared to normal women. In early follicular phase of all of PCOD patients, serum levels LH were always higher than those of FSH. Serum PRL levels were shown to be significantly (p < 0.05) higher in PCOD patients than in normal women. Although the cause of both inappropriate gonadotropin secretion and occurrence of mild hyperprolactinemia in PCOD have not been fully elucidated, decrease in numbers of receptor for dopamine is thought to be one of the main causes of them from the present data obtained by metoclopramide injection administered during the continuous infusion of dopamine.

          Related collections

          Author and article information

          Journal
          HRE
          Horm Res Paediatr
          10.1159/issn.1663-2818
          Hormone Research in Paediatrics
          S. Karger AG
          978-3-8055-5262-2
          978-3-318-01975-9
          1663-2818
          1663-2826
          1990
          1990
          02 December 2008
          : 33
          : Suppl 2
          : 5-9
          Affiliations
          Department of Obstetrics and Gynecology, Hokkaido University School of Medicine, Sapporo, Japan
          Article
          181557 Horm Res 1990;33:5–9
          10.1159/000181557
          2128882
          7d256b91-8e2d-46fe-91ba-45cc4faf8ee5
          © 1990 S. Karger AG, Basel

          Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

          History
          Page count
          Pages: 5
          Categories
          New Aspects of Pathophysiology and Treatment of Polycystic Ovary Syndrome

          Endocrinology & Diabetes,Neurology,Nutrition & Dietetics,Sexual medicine,Internal medicine,Pharmacology & Pharmaceutical medicine
          PRL,PCOD,Dopamine,Gonadotropins,Metoclopramide

          Comments

          Comment on this article